Terminal α2,6-sialylation of epidermal growth factor receptor modulates antibody therapy response of colorectal cancer cells.
Sign Up to like & getrecommendations! Published in 2021 at "Cellular oncology"
DOI: 10.1007/s13402-021-00606-z
Abstract: BACKGROUND The epidermal growth factor receptor (EGFR) is a key protein involved in cancer development. Monoclonal antibodies targeting EGFR are approved for the treatment of metastatic colorectal cancer (CRC). Despite the beneficial clinical effects observed… read more here.
Keywords: therapy; terminal sialylation; cancer; sialylation ... See more keywords